Lineage Cell Therapeutics, Inc. announced that preclinical results as part of a surgical development study evaluating the survival and distribution of RG6501 (OpRegen) will be presented at the 2024 Association for Research in Vision and Ophthalmology Annual Meeting (2024 ARVO). The meeting will be held May 5-9, 2024, in Seattle, WA. OpRegen (RG6501) is a suspension of allogeneic retinal pigmented epithelium (RPE) cells currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Subretinal delivery of OpRegen has the potential to counteract RPE cell loss in GA by supporting retinal cell health and improving retinal structure and function. OpRegen is being developed under an exclusive worldwide collaboration between Lineage, and Roche and Genentech, a member of the Roche Group, and is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD ( Identifier: NCT05626114). The ARVO Annual Meeting is the premiere gathering for eye and vision scientists from across the globe, at all career stages, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions.

The theme of the 2024 Annual Meeting addresses how vision research is continually being transformed by new information and technologies. GA and neovascular AMD can occur simultaneously in the same eye, and patients treated for neovascular AMD may still go on to develop GA. GA typically affects both eyes.